What is EXUMA Biotech?
Founded in 2015, EXUMA Biotech Corp operates as a specialized biotechnology research firm headquartered in West Palm Beach, Florida. The company focuses on the development of advanced therapeutic solutions, navigating the complex intersection of clinical research and commercial scalability. By maintaining a lean operational structure while pursuing high-impact scientific breakthroughs, EXUMA Biotech has established a reputation for technical rigor. Its market position is bolstered by a history of successful capital raises, which have enabled the firm to transition from early-stage development to a more mature, enterprise-level operational phase. The company's strategic focus remains on the intersection of innovative drug discovery and the rigorous demands of the global healthcare market.
How much funding has EXUMA Biotech raised?
EXUMA Biotech has raised a total of $167M across 3 funding rounds:
Series A
$37M
Series B
$60M
Stock/Share Issuance
$70M
Series A (2017): $37M with participation from BioAtla, F1 Bioventures, SINOBIOWAY GROUP, and SunTerra Capital
Series B (2021): $60M led by MSD Partners, Americo, and F1 BioVentures
Stock/Share Issuance (2026): $70M, investors not publicly disclosed
Key Investors in EXUMA Biotech
BioAtla
A San Diego-based biotechnology firm specializing in the development of novel monoclonal antibody and cell-based therapeutics through proprietary Conditionally Active Biologics platforms.
F1 Bioventures
A specialized investment entity focused on the research and development sector, providing critical early-stage and growth capital to emerging biotech enterprises.
SunTerra Capital
A Shanghai-based investment firm offering comprehensive M&A financing, investment banking, and strategic consulting services within domestic and international capital markets.
What's next for EXUMA Biotech?
With the successful closure of this major strategic investment, EXUMA Biotech is well-positioned to accelerate its research and development pipeline. The influx of capital is expected to facilitate the expansion of its clinical trial capabilities and the refinement of its core biotechnology platforms. As the company moves into this next phase of growth, stakeholders will likely monitor its ability to translate research milestones into tangible therapeutic outcomes. The firm's history of securing backing from diverse institutional investors suggests a strong foundation for future commercialization efforts and potential long-term value creation in the biotechnology sector.
See full EXUMA Biotech company page
